Wed Sep 25 04:18:48 UTC 2024: ## Journey Medical Outperforms Oculis in Head-to-Head Analysis

**Scottsdale, Arizona – September 25, 2024** – In a recent analysis, MarketBeat News compared two small-cap medical companies, Oculis (NASDAQ: OCS) and Journey Medical (NASDAQ: DERM), to determine which stock offers a better investment opportunity. While analysts predict a higher potential upside for Oculis, Journey Medical emerges as the stronger performer based on key financial metrics.

**Journey Medical Wins on Revenue, Earnings, and Valuation**

Despite Oculis boasting a higher potential upside, Journey Medical currently boasts higher revenue and earnings. Additionally, Journey Medical trades at a lower price-to-earnings ratio, suggesting it is more affordable at present.

**Journey Medical Excels in Profitability and Volatility**

Journey Medical also outperforms Oculis in terms of profitability, with better net margins, return on equity, and return on assets. Furthermore, Journey Medical exhibits lower volatility compared to Oculis, with a beta of 0.9 versus Oculis’ 0.3. This suggests Journey Medical’s stock price is less susceptible to market fluctuations.

**Institutional and Insider Confidence**

While Oculis has a slightly higher percentage of institutional ownership, Journey Medical enjoys strong support from both institutional and insider investors. This indicates significant confidence in the company’s future prospects from large money managers, endowments, and hedge funds.

**Company Profiles**

Oculis is a clinical-stage biopharmaceutical company developing treatments for ophthalmic diseases. Its lead candidates are in clinical trials for diabetic macular edema, dry eye disease, and neurological damage.

Journey Medical focuses on developing and commercializing pharmaceutical products for dermatological conditions in the United States. The company has several marketed products for conditions such as hyperhidrosis, acne, rosacea, and fungal infections.

**Conclusion**

Based on the analysis, Journey Medical appears to be the superior investment opportunity at this time. While Oculis holds potential for future growth, Journey Medical boasts stronger financial performance, a more favorable valuation, and higher confidence from institutional and insider investors.

**Disclaimer:** This article is for informational purposes only and does not constitute investment advice. Always consult with a qualified financial advisor before making any investment decisions.

Read More